Fractalkine/CX3CL1: A Potential New Target for Inflammatory Diseases
- 1 October 2010
- journal article
- review article
- Published by CLOCKSS Archive in Molecular Interventions
- Vol. 10 (5), 263-270
- https://doi.org/10.1124/mi.10.5.3
Abstract
A better understanding of the immunological processes governed by cytokines and chemokines has shaped our approach to the design of therapeutics for diseases such as rheumatoid arthritis (RA), atherosclerosis, and other inflammatory disorders. The discovery of chemokines and their receptors as integral components and regulators of inflammation has dramatically contributed to advances in treating these disease states. Among the different classes of chemokines, fractalkine/CX3CL1, with its unique functional and structural characteristics, has been found to participate in inflammation. This viewpoint summarizes the emerging role of fractalkine/CX3CL1 from the historical, functional, and clinical perspective and provides evidence to validate it as a potential therapeutic target in cardiovascular disease, rheumatoid arthritis, as well as other diseases related to vascular inflammation.Keywords
This publication has 57 references indexed in Scilit:
- Rosiglitazone activation of PPARγ suppresses fractalkine signalingJournal of Molecular Endocrinology, 2009
- Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signallingCardiovascular Research, 2009
- Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitisSeminars in Immunopathology, 2009
- Correlation of CX3CL1 and CX3CR1 Levels with Response to Infliximab Therapy in Patients with Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancerGut, 2007
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisThe New England Journal of Medicine, 2006
- Resveratrol Suppresses Tumor Necrosis Factor-α-Induced Fractalkine Expression in Endothelial CellsMolecular Pharmacology, 2006
- Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ductsJournal of Hepatology, 2005
- Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout MiceCirculation, 2003
- Immune Mechanisms in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2001